Investigation on nutrition status and clinical outcome of patients with common cancers in Chinese patients: a multicenter prospective study protocol

Background:Malnutrition is common in patients with cancer, whichadversely affectsthesurvival and quality of life ofcancer patients.However, there is no national data on the prevalence of malnutrition inChinese cancer patients. Thisstudy aims to evaluate the prevalenceof malnutrition and quality of life(QOL)ofChinese patients with localregional, recurrentor metastatic cancer,to address the prognostic value of nutritional status and QOLon the survival of cancer patients in China and to validate the patient-generated subjective global assessment (PG-SGA) questionnaire in Chinese cancer patients.Methods:Thisisanobservational,multi-centered,and hospital-based prospective cohort study.We aimed to recruit 50,000 cancer patients (age 18and above)overan 8-year period.Data collection will occur within 48hrafter patientsare admitted to hospital, 30-days after hospital admission, and the follow-up will be conducted1-8years after enrolment. The primary outcomeisoverall survival, and secondaryoutcomes arelength of hospital stay and hospital costs. Factors measured are demographic characteristics, tumor characteristics, anthropometry measurements,hematological measurement, body composition, PG-SGAscores,Karnofsky performance status scores,and QLQ C30 scores. This protocol wasapproved by local ethical committees of all the participant hospitals.Conclusions: This multi-centered, large-scale, long-time follow-up prospective study will help diagnose malnutrition in cancer patients in China, and identify the related risk factors associated with the negative outcomes. The anticipated results will highlight the need for a truly scientific appraisal of nutrition therapy, and help to improve outcomes among cancer patients in China.Trial Registration: The trial has been registered with the Chinese Clinical Trial Registry, ChiCTR1800020329. Registered on 19 December 2018

The incidence and risk factors associated with sarcopenia in maintenance hemodialysis patients / 肠外与肠内营养

Objective:To investigate the incidence and related factors with sarcopenia in maintenance hemodialysis patients.Methods:A total of 131 patients with non-hospitalized maintenance hemodialysis who had been maintained for at least 3 months and in a stable condition were enrolled in a cross-sectional study.Bioelectric impedance analysis (BIA) method was employed to examine the muscle mass.MQSGA questionnaire was used to evaluate patients'nutrition status as well as related laboratory indicators.Logistic regression was used to analyze the risk factors of sarcopenia in MHD patients.Results:The incidence of sarcopenia in 131 MHD patients was 41.22％ (54/131).Significant differences were observed in gender,duration of hemodialysis,hs-CRP and the score of M(Q)SGA between the two groups.The incidence of sarcopenia in male was 43.67 times compared with female.And with the increase of hs-CRP levels and MQSGA score,the incidence of sarcopenia was increased as well (P ＜0.05).Conclusion:Sarcopenia has a high incidence in MHD patients,and male,micro-inflammatory state and malnutrition were the risk factors.

Using KDQOL-SFTM[1]1.2 Scale to Study the Life Quality of End Stage Renal Disease Patients / 昆明医科大学学报

Objective To investigate the life quality (QoL) of end stage renal disease patients. Methods KDQOL-SFTM1.2 scale was used to assess the life quality of end-stage renal disease patients who received maintenance hemodialysis or Newly diagnosed but not yet received renal replacement therapy more than three months in the First Affiliated Hospital of Kunming Medical University or the Yunnan Kidney Disease Hospital from March 2011 to July 2012. Results (1) The QoL of maintenance hemodialysis group was significantly higher than not yet started renal replacement therapy group in the Physical functioning (PF),Role physical (RP),Body pain (BP) fields, the difference was statistically significant ( <0.05) . (2) The QoL of maintenance hemodialysis group was significantly higher than not yet started renal replacement therapy group in the Symptom/problem list (SPL), Sleep fields,but lower than not yet started renal replacement therapy group in the Effects of Kidney disease (EKD), Work status (WS) fields,the difference was statistically significant (<0.05) . Conclusion The life quality of maintenance hemodialysis patients is higher than newly diagnosed but not yet started renal replacement therapy patients in some aspects.

Quality of Life and Influence Factors Analysis of Kidney Transplantation Patients and Hemodialysis Patients / 昆明医科大学学报

Objective Investigate the quality of life (QoL) and its related factors of end stage renal disease (ESRD) patients subjected to kidney transplantation or hemodialysis. Methods From March 2011 to July 2012, patients subjected to kidney transplantation or hemodialysis more than three months hospitalized in the first affiliated hospital of Kunming Medical University and the Yunnan Kidney Disease Hospital were enrolled. Their biochemical indexes were determined and questionnaire survey was performed using KDQOL-SFTM1.2 scale to assess the QoL of ESRD patients. Results (1) The QoL of renal transplantation group was significantly higher than hemodialysis group in the 36-item health survey (SF-36),its physiological and psychological field scores,and the difference was statistically significant ( <0.001);(2) The QoL of renal transplantation group was significantly higher than hemodialysis group in the kidney disease-targeted scales (KDTA) and its fields excepting cognitive function (CF), quality of social interaction (QSI) and sleep field, and the difference was statistically significant ( <0.001); (3) Correlation analysis showed that the scores of SF-36 and KDTA in two groups were positively associated with albumin (Alb) but negatively associated with age. The scores of SF-36 in two groups were positively associated with hemoglobin (Hb) and degree of education. Conclusion The results showed that the QoL of kidney transplantation patients was much higher than that of hemodialysis patients.

The study of the sensitive and specificity on HBV DNA replication by HBV-lP detecting / 中华实验和临床病毒学杂志

<p><b>OBJECTIVE</b>To detect HBV-LP and HBV DNA of the patients with hepatitis B, and to study the sensitive and specificity of HBV-LP detecting and its evaluate on for clinical application.</p><p><b>METHODS</b>The ELISA was used for HBV-LP detecting and RT-PCR for HBV DNA detecting.</p><p><b>RESULTS</b>The sensitive and specificity of HBV-LP and HBV DNA were 64.89%, 99.68%, 60.63% and 100% respectively (P > 0.05); +LR, -LR were 202.78, 60.63, 0.3522 and 0.3937, and there were significance between +LR of the detecting (P < 0.005).</p><p><b>CONCLUSION</b>The sensitive and specificity of HBV-LP and HBV DNA detecting are considerable, +LR of HBV-LP are higher comparing HBV DNA. The HBV-LP is better serology index for detecting replication of HBV DNA.</p>

Treatment of non-small-cell lung cancer with paraplatin given by two different dosage calculation methods / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To study the reasonable dosage for paraplatin according to different dosage calculations.</p><p><b>METHODS</b>A prospective, randomized, single-blinded study on 54 patients with advanced non-small-cell lung cancer (NSCLC) treated with paraplatin was conducted. Patients were divided to 2 groups. In group A, paraplatin dosage was calculated according to patients' body surface, and in group B, it was calculated according to the area under the curve (AUS). Hematological toxicity, response rate and survival rate in the two groups of patients were compared.</p><p><b>RESULTS</b>Neutropenia in group A and group B was seen in 77.8% and 37.0% (P < 0.05), and thrombocytopenia in 18.5% and 3.7% (P > 0.05) of patients, respectively. Hemoglobin decrease was seen in 48.2% of patients in both groups. The average quantity of paraplatin given in one cycle of treatment was 535.93 +/- 106.71 mg and 398.52 +/- 71.72 mg (P < 0.01) respectively. The average time interval between treatment cycles was 27.04 +/- 5.30 d and 22.85 +/- 2.80 d (P < 0.05). The response rate and survival rate of patients in group A and B were 22.2% versus 48.2% (P < 0.05), and 40.7% versus 44.4% (P > 0.05) respectively, but the median survival time was identical (12 months) in the two groups.</p><p><b>CONCLUSION</b>NSCLC patients given paraplatin with dosages calculated on the basis of AUC have higher response rate and less severe hematological toxicity than those given paraplatin with dosages on the basis of body surface. However, the median survival time and survival rate have no statistical differences between the two groups of patients.</p>